Product Description
an investigational therapy for sickle cell disease (SCD) (Sourced from: https://ashpublications.org/ashclinicalnews/news/2915/Vepoloxamer-Does-Not-Meet-Primary-Endpoint-in)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Savara
Company Location: AUSTIN TX 78746
Company CEO: Matthew Pauls
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anemia, Sickle Cell
Phase 2: Other|Heart Failure, Chronic
Phase 1: Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Evaluation of Purified Poloxamer 188 in Subjects in Crisis (EPIC) | P3 |
Completed |
Anemia, Sickle Cell |
2017-01-16 |
2022-03-13 |
Treatments |
|
| MST-188-07 | P2 |
Terminated |
Other |
2016-12-01 |
2019-03-20 |
Treatments |
|
| MST-188-10 | P1 |
Completed |
Kidney Diseases |
2016-11-01 |
2019-03-20 |
Treatments |
|
| MST-188-09 | P2 |
Terminated |
Heart Failure, Chronic |
2016-10-01 |
2019-03-20 |
Treatments |
|
| EPIC-E | P3 |
Completed |
Anemia, Sickle Cell |
2016-09-01 |
2019-03-20 |
Treatments |
|
| Evaluation of MST-188 in Acute Lower Limb Ischemia | P2 |
Terminated |
Unknown |
2016-05-05 |
2022-03-13 |
Treatments |
|
| EPIC | P3 |
Completed |
Anemia, Sickle Cell |
2016-02-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/31/2024 |
PubMed |
Effects of poloxamer 188 on traumatic brain injury. |
|
02/01/2024 |
PubMed |
Vepoloxamer improves functional recovery in rat after traumatic brain injury: A dose-response and therapeutic window study. |
|
10/06/2023 |
PubMed |
Treatment of stroke in aged male and female rats with Vepoloxamer and tPA reduces neurovascular damage. |
|
10/21/2019 |
News Article |
Vaso-Occlusive Crisis Pipeline Insight Report 2019 - ResearchAndMarkets.com |